NOT FOR HUMAN CONSUMPTION

Human chorionic gonadotropin(HCG) a glycoprotein hormone (α/β subunits) that acts as a potent LH-receptor (LHCGR) agonist. In ovaries it triggers final oocyte maturation/ovulation and supports the corpus luteum; in testes it stimulates Leydig cells → testosterone and, with FSH, spermatogenesis. hCG is prescription-only; formulations include urinary-derived (u-hCG) and recombinant (r-hCG).

Additional Benefits of hCG Now Under Investigation

Benefit	Key take-aways
1 Male hypogonadotropic hypogonadism (HH)	hCG restores intratesticular T and supports spermatogenesis when combined with FSH; monotherapy can normalize serum T and libido/energy in HH while preserving fertility potential. <br/><em>JCEM; Endocrine Reviews</em>
2 Fertility preservation during testosterone therapy	Low-dose adjunct hCG can maintain intratesticular T, testicular volume, and sperm production in men receiving exogenous testosterone who wish to avoid azoospermia. <br/><em>Fertility and Sterility; Andrology</em>
3 Induction of spermatogenesis after AAS suppression	Post–anabolic steroid or prolonged TRT, hCG ± FSH protocols help re-initiate spermatogenesis over months. <br/><em>Human Reproduction; Translational Andrology & Urology</em>
4 Prepubertal cryptorchidism (select cases)	hCG can promote testicular descent in some boys (variable success); surgical orchiopexy remains standard. <br/><em>Pediatrics; European Urology</em>
5 Female ART trigger	In IVF, r-hCG/u-hCG reliably triggers final oocyte maturation; kisspeptin or GnRH agonistmay be used in high-OHSS-risk patients. <br/><em>Human Reproduction Update; Reproductive Biomedicine Online</em>
6 Luteal support (adjunct)	hCG can support early luteal progesterone production; modern programs often prefer progesterone to reduce OHSS risk. <br/><em>F&S Reviews; Cochrane</em>
7 Hypogonadism with fertility intent	In functional/secondary hypogonadism (obesity, opioids), hCG can raise T while retaining fertility, sometimes avoiding TRT. <br/><em>Frontiers in Endocrinology; Clinical Endocrinology</em>
8 Diagnostic uses	hCG stimulation tests assess Leydig cell reserve or steroidogenesis in ambiguous genitalia/CAH workups. <br/><em>Best Practice & Research Clinical Endocrinology & Metabolism</em>
9 Onco-fertility	In men treated for pituitary/cranial tumors, hCG±FSH helps re-establish fertility when gonadotropins recover poorly. <br/><em>Annals of Oncology; Endocrine Connections</em>

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

LHCGR (GPCR) agonist → Gs → cAMP/PKA → steroidogenesis (↑ StAR, CYP11A1) and gamete maturation.
In testes: Leydig cells → testosterone; Sertoli support via paracrine crosstalk (FSH still required for full spermatogenesis).
In ovaries: The “LH surge mimic” for oocyte maturation, luteinization, and progesterone output.

2.2 Down-stream Biology

Pathway	Functional outcome	Context
cAMP/PKA → StAR/CYP enzymes	↑ Testosterone / ↑ Progesterone	Testis / Ovary
Paracrine Sertoli support	Spermatogenic progression (with FSH)	Testis
Cumulus expansion/meiotic resumption	Final oocyte maturation	ART trigger

3. Pharmacokinetics

Route: SC or IM.
Half-life: u-hCG ~24–36 h; r-hCG similar, enabling once-every-1–3-day dosing (men) or single trigger dose (women).
Detection: Prolonged biologic activity; relevant for anti-doping (detectable for days).

4. Pre-clinical and Clinical Evidence

4.1 Male HH & Fertility

Sequential hCG → +FSH regimens restore T, testicular volume, and sperm counts; pregnancy rates improve over 6–18 months depending on baseline testicular size, cryptorchidism history, and adherence.

4.2 Men on TRT desiring fertility

Adjunct low-dose hCG maintains intratesticular T and mitigates testicular atrophy; if azoospermic, add FSH and time.

4.3 Female ART

r-hCG is a gold-standard trigger; however, OHSS risk rises in high responders, GnRH-agonist trigger or kisspeptinmay be safer in such cases.

Evidence quality note: Strong, guideline-level support for HH, ART trigger, and fertility preservation; variable/limited utility for cryptorchidism and functional hypogonadism depends on phenotype.

5. Emerging Clinical Interests

Field	Rationale	Status
Opioid-induced androgen deficiency	Preserve fertility, raise T without TRT	Small studies
Obesity-related secondary hypogonadism	LHCGR drive with lifestyle/GLP-1 adjuncts	Exploratory
Female hypoactive sexual desire (hCG-progesterone milieu)	Hormonal orchestration hypotheses	Very early
hCG micro-dosing in ART	Fine-tuning luteal support	Program-dependent

6. Safety and Tolerability

Common: Injection-site pain, headache, mood lability, fatigue, acne/oiliness (from ↑ androgens in men), breast tenderness.
Men: Gynecomastia (via aromatization), erythrocytosis (rare vs TRT), worsening OSA in predisposed, testicular ache early in therapy.
Women: Ovarian hyperstimulation syndrome (OHSS) risk post-trigger (ascites, hemoconcentration), multiple gestation risk if not carefully managed.
Cardio-metabolic: Monitor BP, lipids, glucose when androgens rise.
Psych: Mood changes/irritability in a subset.
Contraindications: Hormone-sensitive cancers, pregnancy (outside ART indication), active thromboembolic disease, uncontrolled endocrine disorders.
Drug interactions: Additive androgenic effects with AAS/TRT; aromatase inhibitors/SERMs sometimes co-used to manage estradiol/gynecomastia in men aiming at fertility.

Comparative safety matrix

Feature	hCG	Testosterone (TRT)	FSH (uFSH/rFSH)	GnRH agonist
Fertility while treating hypogonadism	Preserved	Suppresses(azoospermia risk)	Supports spermatogenesis	Stimulates axis (if intact)
Primary target	LH receptor	Androgen receptor	FSH receptor	Pituitary GnRH receptor
Key risk	Gynecomastia / OHSS (women)	Erythrocytosis, infertility	Cost, injections	Flare, hypoestrogenic sx
Use in ART	Trigger / luteal support	No	Ovarian stimulation	Trigger (alt), down-reg

7. Regulatory & Anti-Doping Landscape

Approvals: Widely approved for male HH, induction of ovulation/ART trigger, and cryptorchidism (regional differences).
Weight-loss warning: The “hCG diet” has been discredited; FDA/FTC warn against hCG for weight loss, no efficacy, unnecessary risk.
Sport: Prohibited by WADA in males (can mask or restore T after AAS) and is detectable; sanctions are common.

8. Future Directions

Personalized male fertility protocols: Optimizing hCG+FSH schedules by baseline testicular volume, AMH/inhibin B, and genetics.
Adjuncts to reduce OHSS: Wider adoption of GnRH-agonist/kisspeptin triggers and tailored luteal support instead of high-dose hCG in high responders.
Functional hypogonadism trials: Head-to-head hCG vs TRT (QoL, metabolic outcomes, fertility metrics).
Long-acting r-hCG and self-injector devices to improve adherence and cost-effectiveness.

Selected References

Journal of Clinical Endocrinology & Metabolism; Endocrine Reviews, Diagnosis/management of male hypogonadism and use of hCG ± FSH for fertility.
Fertility and Sterility; Human Reproduction Update, IVF trigger strategies (hCG vs GnRH-agonist vs kisspeptin) and OHSS mitigation.
Andrology; Human Reproduction, Fertility preservation during TRT using low-dose hCG; recovery after AAS.
Pediatrics; European Urology, Cryptorchidism medical therapy evidence and limitations.
Best Practice & Research Clin Endocrinol Metab, hCG stimulation tests in disorders of sex development/steroidogenesis.
FDA/FTC notices; Obesity, Warnings against the hCG diet and lack of weight-loss efficacy.
WADA / Drug Testing & Analysis, Prohibited status, detection methods, and case report

Human chorionic gonadotropin(HCG) 5000iu vial

Complete the setup